dc.contributor.author | Lambros, MB | |
dc.contributor.author | Seed, G | |
dc.contributor.author | Sumanasuriya, S | |
dc.contributor.author | Gil, V | |
dc.contributor.author | Crespo, M | |
dc.contributor.author | Fontes, M | |
dc.contributor.author | Chandler, R | |
dc.contributor.author | Mehra, N | |
dc.contributor.author | Fowler, G | |
dc.contributor.author | Ebbs, B | |
dc.contributor.author | Flohr, P | |
dc.contributor.author | Miranda, S | |
dc.contributor.author | Yuan, W | |
dc.contributor.author | Mackay, A | |
dc.contributor.author | Ferreira, A | |
dc.contributor.author | Pereira, R | |
dc.contributor.author | Bertan, C | |
dc.contributor.author | Figueiredo, I | |
dc.contributor.author | Riisnaes, R | |
dc.contributor.author | Rodrigues, DN | |
dc.contributor.author | Sharp, A | |
dc.contributor.author | Goodall, J | |
dc.contributor.author | Boysen, G | |
dc.contributor.author | Carreira, S | |
dc.contributor.author | Bianchini, D | |
dc.contributor.author | Rescigno, P | |
dc.contributor.author | Zafeiriou, Z | |
dc.contributor.author | Hunt, J | |
dc.contributor.author | Moloney, D | |
dc.contributor.author | Hamilton, L | |
dc.contributor.author | Neves, RP | |
dc.contributor.author | Swennenhuis, J | |
dc.contributor.author | Andree, K | |
dc.contributor.author | Stoecklein, NH | |
dc.contributor.author | Terstappen, LWMM | |
dc.contributor.author | de Bono, JS | |
dc.date.accessioned | 2019-04-24T08:33:47Z | |
dc.date.issued | 2018-11-15 | |
dc.identifier.citation | Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 24 (22), pp. 5635 - 5644 | |
dc.identifier.issn | 1078-0432 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3199 | |
dc.identifier.eissn | 1557-3265 | |
dc.identifier.doi | 10.1158/1078-0432.ccr-18-0862 | |
dc.description.abstract | Purpose: Circulating tumor cells (CTCs) have clinical relevance, but their study has been limited by their low frequency.Experimental Design: We evaluated liquid biopsies by apheresis to increase CTC yield from patients suffering from metastatic prostate cancer, allow precise gene copy-number calls, and study disease heterogeneity.Results: Apheresis was well tolerated and allowed the separation of large numbers of CTCs; the average CTC yield from 7.5 mL of peripheral blood was 167 CTCs, whereas the average CTC yield per apheresis (mean volume: 59.5 mL) was 12,546 CTCs. Purified single CTCs could be isolated from apheresis product by FACS sorting; copy-number aberration (CNA) profiles of 185 single CTCs from 14 patients revealed the genomic landscape of lethal prostate cancer and identified complex intrapatient, intercell, genomic heterogeneity missed on bulk biopsy analyses.Conclusions: Apheresis facilitated the capture of large numbers of CTCs noninvasively with minimal morbidity and allowed the deconvolution of intrapatient heterogeneity and clonal evolution. Clin Cancer Res; 24(22); 5635-44. ©2018 AACR. | |
dc.format | Print-Electronic | |
dc.format.extent | 5635 - 5644 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | AMER ASSOC CANCER RESEARCH | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Prostatic Neoplasms | |
dc.subject | Cell Transformation, Neoplastic | |
dc.subject | Blood Component Removal | |
dc.subject | Cell Count | |
dc.subject | Cell Separation | |
dc.subject | In Situ Hybridization, Fluorescence | |
dc.subject | Genetic Heterogeneity | |
dc.subject | Male | |
dc.subject | Neoplastic Cells, Circulating | |
dc.subject | Comparative Genomic Hybridization | |
dc.subject | Single-Cell Analysis | |
dc.subject | High-Throughput Nucleotide Sequencing | |
dc.subject | Biomarkers, Tumor | |
dc.subject | Liquid Biopsy | |
dc.title | Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2018-07-18 | |
rioxxterms.versionofrecord | 10.1158/1078-0432.ccr-18-0862 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2018-11 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Clinical cancer research : an official journal of the American Association for Cancer Research | |
pubs.issue | 22 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Glioma Team | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Translational Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Glioma Team | |
pubs.organisational-group | /ICR/Students | |
pubs.organisational-group | /ICR/Students/PhD and MPhil | |
pubs.organisational-group | /ICR/Students/PhD and MPhil/16/17 Starting Cohort | |
pubs.organisational-group | /ICR/Students/PhD and MPhil/18/19 Starting Cohort | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Glioma Team | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Translational Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Glioma Team | |
pubs.organisational-group | /ICR/Students | |
pubs.organisational-group | /ICR/Students/PhD and MPhil | |
pubs.organisational-group | /ICR/Students/PhD and MPhil/16/17 Starting Cohort | |
pubs.organisational-group | /ICR/Students/PhD and MPhil/18/19 Starting Cohort | |
pubs.publication-status | Published | |
pubs.volume | 24 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Cancer Biomarkers | |
icr.researchteam | Prostate Cancer Targeted Therapy Group | |
icr.researchteam | Translational Therapeutics | |
icr.researchteam | Glioma Team | |
dc.contributor.icrauthor | Seed, George | |
dc.contributor.icrauthor | Sumanasuriya, Semini | |
dc.contributor.icrauthor | Miranda, Susana | |
dc.contributor.icrauthor | Mackay, Alan | |
dc.contributor.icrauthor | Pereira, Ana Rita | |
dc.contributor.icrauthor | Sharp, Adam | |
dc.contributor.icrauthor | Goodall, Jane | |
dc.contributor.icrauthor | Carreira, Suzanne | |
dc.contributor.icrauthor | Rescigno, Pasquale | |
dc.contributor.icrauthor | De Bono, Johann | |